Dr Emily Johnson from Johns Hopkins University School of Medicine talks about her research on late-onset epilepsy, the midlife risk factors that may contribute to late-onset epilepsy, and more.
Dr Emily Johnson from Johns Hopkins University School of Medicine talks about her research on late-onset epilepsy, the midlife risk factors that may contribute to late-onset epilepsy, and more.
Marcel Daadi, PhD, from Texas Biomedical Research Institute, talks about his life-long research into dopaminergic neurons for treating Parkinson disease and whether it is possible to replenish dopamine loss in the brain.
Marcel Daadi, PhD, from Texas Biomedical Research Institute, talks about his life-long research into dopaminergic neurons for treating Parkinson disease and whether it is possible to replenish dopamine loss in the brain.
In the final installment of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA, discusses suicidality in patients with schizophrenia compared with the general population. He also outlines steps...
In the final installment of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA, discusses suicidality in patients with schizophrenia compared with the general population. He also outlines steps...
In part 3 of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA explains the importance of treating his patients’ physical and societal health in addition to their psychiatric health.
In part 3 of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA explains the importance of treating his patients’ physical and societal health in addition to their psychiatric health.
Schizophrenia is not a death sentence, says Robert S Laitman, MD, from Bronx Westchester Medical Group and SARDAA. In part 2 of this podcast series, Dr Laitman explains how his approach to treatment has helped the majority of his patients...
Schizophrenia is not a death sentence, says Robert S Laitman, MD, from Bronx Westchester Medical Group and SARDAA. In part 2 of this podcast series, Dr Laitman explains how his approach to treatment has helped the majority of his patients...
In part 1 of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA, discusses the 5 criteria used to help diagnose schizophrenia, as well as the differential diagnosis.
In part 1 of this podcast series, Robert S. Laitman, MD, from Bronx Westchester Medical Group and SARDAA, discusses the 5 criteria used to help diagnose schizophrenia, as well as the differential diagnosis.
Ilya Kister, MD, from NYU Langone Health in New York City, discusses his research into the predictors of multiple sclerosis relapse and disability progression in patients who stop disease-modifying therapies.
Ilya Kister, MD, from NYU Langone Health in New York City, discusses his research into the predictors of multiple sclerosis relapse and disability progression in patients who stop disease-modifying therapies.
Dr Chiara Manzini, from the George Washington University Institute for Neuroscience, shares insight from her research into the physiologic and genetic mechanisms behind why neurodevelopmental disorders such as autism are more prevalent in the...
Dr Chiara Manzini, from the George Washington University Institute for Neuroscience, shares insight from her research into the physiologic and genetic mechanisms behind why neurodevelopmental disorders such as autism are more prevalent in the...
In patients with acute ischemic stroke eligible for intravenous thrombolysis within 4.5 hours of symptom onset, tenecteplase was noninferior to alteplase for achieving an excellent functional outcome at day 90.
In patients with acute ischemic stroke eligible for intravenous thrombolysis within 4.5 hours of symptom onset, tenecteplase was noninferior to alteplase for achieving an excellent functional outcome at day 90.
Intravenous Lu AG09222 reduced migraine frequency over 4 weeks in patients who had failed to find relief with previous treatments, according to a phase 2 trial published in the New England Journal of Medicine.
Intravenous Lu AG09222 reduced migraine frequency over 4 weeks in patients who had failed to find relief with previous treatments, according to a phase 2 trial published in the New England Journal of Medicine.
Patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping demonstrated unprecedented dystrophin expression and functional improvement with the investigational therapeutic DYNE-251.
Patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping demonstrated unprecedented dystrophin expression and functional improvement with the investigational therapeutic DYNE-251.
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Patients with MS had about half the rate of amyloid pathology compared with matched control subjects in the Washington University School of Medicine study.
Patients with MS had about half the rate of amyloid pathology compared with matched control subjects in the Washington University School of Medicine study.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
As millions of Americans, both children and adult, prepare to return to school next week, an ongoing challenge has once again reared its head: a shortage of stimulant drugs used to treat attention-deficit/hyperactivity disorder (ADHD).
As millions of Americans, both children and adult, prepare to return to school next week, an ongoing challenge has once again reared its head: a shortage of stimulant drugs used to treat attention-deficit/hyperactivity disorder (ADHD).
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click